Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin

Highlights • Circulating nucleosomes and survivin are elevated in sera of patients with locally confined and metastatic breast cancer. • Cytokeratin-18 fragments (M30-antigen) and breast tumor markers CEA and CA 15-3 are only elevated in metastatic disease. • High pretherapeutic nucleosome levels in...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2013-08, Vol.336 (1), p.140-148
Main Authors: Stoetzer, Oliver J, Fersching, Debora M.I, Salat, Christoph, Steinkohl, Oliver, Gabka, Christian J, Hamann, Ulrich, Braun, Michael, Feller, Axel-Mario, Heinemann, Volker, Siegele, Barbara, Nagel, Dorothea, Holdenrieder, Stefan
Format: Article
Language:English
Subjects:
Adult
Aged
Apoptosis
Apoptotic biomarkers
Biomarkers
Biomarkers, Tumor - blood
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Cancer therapies
Carcinoembryonic Antigen - blood
Chemotherapy
Cytokeratin fragments
Cytotoxicity
Deoxyribonucleases - metabolism
Female
Hematology, Oncology and Palliative Medicine
Humans
Inhibitor of Apoptosis Proteins - blood
Keratin-18 - blood
Lung cancer
Medical prognosis
Middle Aged
Mucin-1 - blood
Neoadjuvant chemotherapy
Neoadjuvant Therapy - methods
Nucleosomes
Nucleosomes - metabolism
Sensitivity and Specificity
Surgery
Survivin
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Circulating nucleosomes and survivin are elevated in sera of patients with locally confined and metastatic breast cancer. • Cytokeratin-18 fragments (M30-antigen) and breast tumor markers CEA and CA 15-3 are only elevated in metastatic disease. • High pretherapeutic nucleosome levels indicate poor response to neoadjuvant chemotherapy. • Apoptotic biomarkers bear valuable information for diagnosis and therapy response in breast cancer patients.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2013.04.013